Background: Abdominal obesity and hypertriglyceridemia (the hypertriglyceridemic-waist phenotype) increase cardiovascular risk. The very low-density lipoprotein (VLDL) is a triglyceride (TG)-rich particle. Frequent variations in the genes coding for enzymes and proteins involved in the VLDL catabolism have already been documented. The epistatic effect of such variants on the risk profile associated with abdominal obesity remains to be elucidated. Objective: This study aims to assess the effect of combinations of frequent single-nucleotide polymorphisms (SNPs) in the VLDL catabolic pathway on the relation between abdominal obesity and fasting TG. Method: Only gene variants in the lipoprotein lipase, apolipoprotein (apo) CIII, hepatic lipase and apo E genes known to be frequent in the general population (allele frequency45%) were included in this study. The presence of selected SNPs was detected by polymerase chain reaction-restriction fragment length polymorphisn in a sample of 640 non-diabetic French Canadians at high cardiovascular risk (405 obese, 235 non-obese). Results: Carrying more than two frequent gene variants involved in the VLDL catabolic pathway significantly increased the risk of hyperTG (odds ratio of TG41.7 mmol/l ¼ 4.15; P ¼ 0.001). This effect was proportional to the number of SNPs and genes involved and was significantly amplified by the presence of abdominal obesity defined on the basis of waist circumference. Conclusion: When combined with abdominal obesity, epistasis in the VLDL pathway has a deleterious effect on fasting TG and coronary artery disease risk profile according to the TG threshold (1.7 mmol/l) used in medical guidelines for the assessment of the metabolic syndrome and associated risk.
Introduction
Several markers are available to assess coronary artery disease (CAD) risk. In particular, an atherogenic triad combining hyperapolipoprotein B (hyperapo B), small and dense lowdensity lipoproteins (LDL), and hyperinsulinemia was found to be effective in identifying high-risk CAD patients. 1 However, measurement of these variables is expensive and not always available to clinicians. In this regard, it has recently been suggested that the 'hypertriglyceridemic-waist' phenotype, in which subjects are characterized by a waist circumference over 90 cm in men and over 85 cm in women combined with hypertriglyceridemia (hyperTG), was a simple and easily available correlate of the metabolic atherogenic triad and CAD risk. [2] [3] [4] Several pathways are involved in the expression of the atherogenic triad and may contribute to the CAD risk. This is the case for the triglyceride (TG)-rich very low-density lipoprotein (VLDL) catabolic pathway. The catabolic cascade of the VLDL particle sequentially involves several enzymes, regulatory elements and apolipoproteins (apo), each coded by a specific gene ( Figure 1 ). In many of these genes, several single-nucleotide polymorphisms (SNPs) have already been documented, some of them having been reported as frequent (45%) in the general population, thus increasing the odds of simultaneously carrying two or more of these SNPs. As the independence of common gene variants transmission is most often associated with independence of the effect, this is not always relevant from a clinical or public health standpoint. However, in a sequential metabolic cascade such as the VLDL catabolic pathway, the combined effect of gene variations acting in the same direction can be synergistic on the risk profile. Furthermore, in a context of independence of transmission, such combinations can be frequent in the general population, contributing to the clinical and public health utility of such information. The aim of this study was thus to estimate the effect of different combinations of gene variants involved in the VLDL metabolism on the expression of the 'hypertriglyceridemic-waist' phenotype in a sample of 640 non-diabetic French Canadians. Specifically, we have assessed fasting TG concentrations associated with combinations of frequent SNPs in genes involved in the VLDL catabolic cascade, in relation to the level of abdominal obesity (defined by a waist circumference X90 cm in men and X85 cm in women). Gene variants were selected on the basis of their allele frequency (45%) in the general population, as estimated in a random sample of the Cardiovascular Study of Santé Québec (1991). The selected variants were lipoprotein lipase (LPL) gene variants (D9N, N291S and P207L), the apo CIIISstI, the hepatic lipase (HL)-T514 allele (HL-514 C/T), the peroxisome proliferator-activated receptor (PPAR)a-V162 allele (PPARa-L162 V), the PPARg-A12 allele (PPARg-P12A) and the apo e2 and apo e4 alleles. The analyses showed that, individually, LPL variants (D9N, N291S and P207L), the apo CIII-SstI, the HL-T514 allele and the apo e2 allele were associated with a significant elevation of plasma TG concentrations. The combination of two or more of these hyperTG variants had an incremental effect on plasma TG. The influence of these gene variants and their combination on plasma TG was significantly exacerbated by the presence of abdominal obesity, defined on the basis of waist circumference.
Methods

Subjects and clinical data
This study comprised a sample of 640 French-Canadian untreated subjects (354 men and 286 women) from the Saguenay-Lac-Saint-Jean region (Quebec, Canada), selected on the basis of having a positive family history of dyslipidemia, CAD or type 2 diabetes. All subjects were followed at the Chicoutimi Hospital Lipid Clinic and had agreed to participate in studies on genetic determinants of type 2 diabetes or CAD. 5, 6 Subjects homozygous for a null LPL gene mutation, those with familial hypercholesterolemia (FH), the apo e2/e4 genotype, or diagnosed with type 2 diabetes, as well as those taking drugs known to affect blood The prevalence of SNPs in the general population was evaluated among a random sample of 1842 subjects from the Cardiovascular Study of Santé Québec (1991).
Blood samples were obtained after a 12h-overnight fast from the antecubital vein into vacutainer tubes containing ethylenediaminetetraacetic acid. The high-density lipoprotein (HDL) subfraction was obtained after precipitation of the LDL (d41.006 g/ml) in the infranatant with heparin and MnCl 2 .
9 Cholesterol and TG levels were enzymatically measured on a Multiparity Analyzer CX7 (Beckman). Apo B levels were determined using nephelometry. Subjects gave informed consent to participate in this study and were assigned a code systematically denominalizing all clinical data. 10 This project has received the approval of the Chicoutimi Hospital Ethics Committee.
Genotyping
The PPARa-L162 V and PPARg-P12A variants, the presence of P207L, G188E, D9N and N291S variants in the LPL gene and the apo E genotype were identified by a mismatch polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP)-based method, as described previously. 5, [11] [12] [13] [14] [15] [16] The presence of apo CIII-SstI and HL -514 C/T SNPs was identified using the fluorescence polarization detection method. 17 Molecular screening of FH included the detection of nine LDL-receptor gene mutations explaining the majority of cases in the province of Quebec. Two deletions (5 kb and 415 kb) were detected by Southern blotting. 18 The W66G, E207 K, C646Y, C152W, R329X, C347R and Y468X mutations were detected by dot-blot hybridization of genomic DNA amplified by PCR with allelespecific oligonucleotide probes or by PCR-based restriction fragment analysis.
19-21
Statistical analysis Categorical variables were compared using the Pearson w 2 -statistic, whereas group differences for continuous variables were compared with the Student's unpaired two-tailed t-test or an analysis of variance (ANOVA), followed by the Bonferonni post hoc test. Multivariate logistic regression models were built in order to calculate the relative odds of exhibiting plasma TG concentrations above the upper standard limit of 1.7 mmol/l, as defined by several clinical guidelines, 22, 23 associated with the number of carried hyperTG genotypes (namely the apo CIII-SstI, the HL À514 T allele and the apo E2/2 genotype or the apo E2/3 genotype in the presence of an additional primary or secondary dyslipidemic factor), according to waist circumference. The likelihood ratio statistic was used to compare regression models. Odds ratio (OR) are reported. The effects of discrete variables were evaluated dichotomously, according to their absence or presence in subjects. Univariate linear models were also constructed, and the significance of interaction between waist circumference groups and the number of hyperTG genotypes in the resulting models was assessed with an F test. All statistical analyses were performed with the SPSS package (release 11.0, SPSS, Chicago, IL, USA).
Results
The distribution of all hyperTG genotypes was in HardyWeinberg equilibrium and was not affected by gender, except for the HL-514 T allele, which was more frequent among men in this sample. As shown in Table 1 , the apo E4, PPARg-A12 and PPARa-V162 alleles did not significantly affect plasma TG concentrations, whereas the apo CIII-SstI, HL-514 T, apo e2 alleles and all selected LPL variants were associated with increased plasma TG concentrations compared to noncarriers. According to allele frequencies in the general population, 412% of French Canadians are likely to carry two of the selected hyperTG genotypes, whereas 1.3% are potential carriers of three or more of these variants (Table 2) . Table 3 presents subjects' characteristics in relation to the number of hyperTG genotypes carried. As shown, plasma TG levels tended to increase with the number of hyperTG SNPs involved. In the group of subjects carrying more than two hyperTG genotypes, the mean plasma TG concentrations was increased by 2-fold (4.9070.54 mmol/l as compared Figure 2 shows that in the presence of abdominal obesity, combining three or more hyperTG genotypes was associated with an increased risk to exhibit fasting plasma TG concentrations above the threshold (1.7 mmol/l) suggested in clinical guidelines for the diagnosis of the metabolic syndrome and CAD risk assessment (OR ¼ 4.15; P ¼ 0.001). The OR remained comparable when carriers of three or four hyperTG genotypes were analyzed separately (data not shown), and thus the two groups were combined. Among carriers of two genotypes, the risk of hyperTG tended to increase only in the presence of a waist circumference X90 cm in men or X85 cm in women (OR ¼ 1.73; P ¼ 0.05). The risk of hyperTG remained significant when controlling for the type of hyperTG genotype, and the results were independent of the nature of the gene combination considered. However, Table 4 illustrates that although abdominal obesity increases the odds of hyperTG, the distribution of the different combinations of genotypes was not significantly different between the groups of obese vs. non-obese subjects.
The effect of abdominal obesity on the odds of hyperTG (TG41.7 mmol/l) was also tested separately on each hyperTG genotype (Figure 3) . Abdominal obesity was independently associated with an increased plasma TG concentration in LPL, apo E2/2 or apo CIII allele carriers. The independent association of the apo E2 allele with plasma TG concentrations was more complex to assess. Indeed, lean individuals being heterozygous for the apo E2 allele and not carrying another hyperTG genotype tended to have a normal lipid profile, and the odds of finding TG concentrations above 1.7 mmol/l in this group was 0.47 (P ¼ 0.036). In comparison, abdominally obese apo E2 allele carriers, particularly E2 homozygotes or E2 hererozygotes simultaneously carrying another hyperTG genotype, tended to exhibit hyperTG (OR ¼ 2.10; P ¼ 0.07). Figure 4 shows a significant interaction between the number of carried hyperTG genotypes and the presence of a waist girth over 90 cm in men or over 85 cm in women (P ¼ 0.011). The effect on plasma TG tended to be stronger as the number of genotypes increased, especially in abdominally obese subjects.
Discussion
The 'hypertriglyceridemic-waist' phenotype was proposed as a crude marker of a proatherogenic triad (hyperinsulinemia, hyperapo B and dense LDL). 2 This simple clinical phenotype was found to be associated with a X80% probability of bearing the atherogenic metabolic triad features and therefore presenting a higher risk for CAD. 2, 3 We have provided further evidence of a significant contribution of the 'hypertriglyceridemic-waist' phenotype in the modulation of the CAD risk generally associated with hyperglycemia. 4 Several genes have the potential to affect this phenotype. The clinical and public health utility and validity of such genetic determinants remains to be determined. Part of the challenge resides in identifying gene variants (and combination of variants) that may have modest effects on the 'hypertriglyceridemic-waist' relative risk (RR), but bear significant population attributable risks (PAR). Different strategies have been suggested for the identification of multiple loci involved in complex traits. One of them 24 The analytic strategy of the present study, however, is more linear. The approach used to identify gene variants and gene combinations associated with the 'hypertriglyceridemic-waist' phenotype was to target a cascade of events physiologically connected within a sequential cascade, namely the VLDL catabolic pathway. The VLDL particle is a TG-rich apo B-containing lipoprotein. Its catabolism leads to the formation of intermediate-density lipoprotein (IDL) and LDL particles, both associated with a gradient of atherogenicity, which depends on the number and quality (including the density) of these particles. Defects within the VLDL catabolism are well documented and are frequently observed in the presence of abdominal obesity, type 2 diabetes, insulin resistance or CAD. Several enzymes, apolipoproteins, transfer proteins, transducers, regulatory elements and receptors are sequentially involved in the VLDL pathway. Most of the genes coding for these enzymes and proteins have already been identified. Several mutations and polymorphisms have been identified in these genes, some of them being known to interfere with protein production or activity, and to increase plasma apo B or TG concentrations and CAD risk. The allele frequency of these gene variants varies across populations. The gene variants in the VLDL catabolic pathway selected for this study were reported at an allele frequency (AF)45% in different populations, [25] [26] [27] [28] [29] including French Canadians, so that the probability of exhibiting simultaneously two or Figure 2 Estimated risk (odds ratio) to exhibit elevated plasma TG levels (41.7 mmol/l) associated with the presence of frequent combinations of hyperTG genotypes, after stratification for waist circumference. Odds ratios were obtained from multivariate logistic regression analyses taking into account the effect of other TG metabolism confounders, such as age, gender and the presence of coronary artery disease. Subjects with type 2 diabetes or taking medication known to affect plasma TG were excluded from the present study. HyperTG genotypes considered are listed in Table 2 . NS ¼ P40.1. Effect of genotype combinations on triglyceridemia D Brisson et al more of these variants was high enough (46%) to observe and estimate the effect of gene combinations. These gene variants are also known to interfere with the VLDL pathway and contribute to variations in either plasma apo B or TG concentration, type 2 diabetes or CAD risk. [25] [26] [27] These variants were LPL gene variants (D9N, N291S and P207L), the apo CIII-SstI SNP, the HL-T514 allele (HL-514 C/T), the PPARa-V162 allele (PPARa-L162 V), the PPARg-A12 allele (PPARg-P12A) and the apo e2 and apo e4 alleles. The AF values of all the gene variants listed above has been assessed in random samples of the Quebec population. 5, 25, 28, 29 In other populations, the AF of less common alleles for PPARa-V162, apo CIII-SstI and HL-514 C/T SNPs have been estimated at 6.3, 8.6 and 19.3%, respectively, in the Framingham offspring's study, whereas the prevalence of the e2 allele has been reported as high as 10% in several populations. [25] [26] [27] The selected SNPs were presumed to affect the activity of enzymes, transducers or proteins involved in the VLDL catabolism in the same direction (Figure 1) . Interference with the activity of all or any of these enzymes or proteins has the potential to delay TG hydrolysis (LPL, HL), decrease LPL availability for hydrolysis (Apo CIII) or generate interference with receptor recognition by TG-rich VLDL or IDL (apo E2); [25] [26] [27] [28] the most frequent clinical consequence is that the plasma apo B or TG concentration might increase as well as the CAD risk. A recent study has observed that the apo CIII-SstI SNP increases fasting TG levels among carriers of the LPL P207L mutation. 30 Reilly et al. 31 have also recently
shown that subjects who were heterozygotes for four SNPs in three lipase genes (LPL, HL and endothelial lipase) had TG levels beyond the effect of individual lipase SNPs, suggesting a synergistic association. These studies highlight the importance of studying genes in combination.
Our results suggest that the combination of the effect of two or more frequent gene variants involved in the VLDL catabolic pathway has an incremental and synergistic effect on plasma TG, especially in a context where the workload is likely to be increased (as frequently observed in presence of abdominal obesity). In the presence of abdominal obesity, the gene combinations we have studied were associated with a significant increase in fasting plasma TG concentrations above the threshold suggested in different guidelines for the diagnosis of the metabolic syndrome and CAD risk assessment (1.7 mmol/l). 22, 23 This trend remained unchanged when controlling for the type of hyperTG genotype, and the results were independent of the nature of the gene combination considered. Thus, from a clinical standpoint, Figure 3 Estimated risk of hyper TG (OR of plasma TG levels 41.7 mmol/l) associated with frequent hyperTG genotypes considered at the gene level, after stratification for waist circumference. Odds ratios were obtained from multivariate logistic regression analyses taking into account the effect of TG metabolism confounders, such as age, gender and the presence of coronary artery disease. The hyperTG genotypes presented are LPL D9N, N291S and P207L variants (LPL), the apo E2 allele in the absence of abdominal obesity (E2 a) or in the presence of abdominal obesity and additional primary or secondary dyslipidemic factor (E2b), the subgroup of individuals with waist circumference X90 cm for men or X85 cm for women being homozygotes for the apo E2 allele (E2/2), the HL-T514 allele (HL) and the apo CIII-SstI polymorphism (apo CIII). NS refers to a P value 40.1.
Effect of genotype combinations on triglyceridemia D Brisson et al the most significant difference between the different gene combinations studied is not likely to be their specific effect on plasma TG, which appears important but comparable, but may rather reside in other dimensions, including their effect on drug response to lipid-lowering therapy. Indeed, combinations involving the apo E2 allele might be associated with a significantly better and dosage-specific response to both fibrates and statins, as previously suggested by our group and others. 32, 33 The RR of hyperTG associated with each of these frequent genotypes could be modest when considered at the unit level, but a modest effect on the RR could translate into a significant PAR and contribute to a significant proportion of the variance of plasma TG concentrations in the general population. 34 It is obvious that the allele frequency of the selected SNPs will vary from one population to another, thus modifying the relative contribution of the different gene combinations to the PAR across populations. All subjects in our sample were selected from a cohort originally created for the study of genetic determinants of type 2 diabetes or CAD.
Considering that the genotypes studied in the present research are potential modulators of these two phenotypes, [25] [26] [27] [28] we did not expect their allele frequencies in our sample to be comparable with those found in the general population. However, as the biological impact of gene variants appears consistent in magnitude and direction across continents and populations, 35 our sample had the advantage of providing us with a sufficient number of SNP carriers in each group to estimate the risk of hyperTG associated with different SNP combinations. In order to assess their utility and validity, the results presented herein should however be replicated in other studies and in diversified populations. The contribution of frequent alleles affecting the VLDL pathway to the PAR of hyperTG should also be considered in the context of the endemization of obesity worldwide. 36 The present study suggests that abdominal obesity is an important factor worsening the genotypes' effects. This is concordant with our earlier studies. [37] [38] [39] [40] Our results specifically illustrate that combinations of genetic factors sequentially involved in the VLDL catabolic pathway might influence the expression of the 'hypertriglyceridemic-waist' phenotype. Prevention of the risk associated with the 'hypertriglyceridemic-waist' phenotype importantly relies on intervention on life habits (diet, physical activity, etc.) and modifiable risk factors. 41 However, the understanding of the influence of genetic factors (including epistasis) on the expression of this phenotype, or any other element of the Table 2 ), after stratification for waist circumference. (a) Significantly different (Po0.05) as compared to levels measured in groups with no hyperTG genotype (b) with one hyperTG genotype and (c) with two hyperTG genotypes. *P value corresponds to the significance of interaction between the number of hyperTG genotypes carried and waist circumference group. **Corrected for the effect of subjects' age.
Effect of genotype combinations on triglyceridemia D Brisson et al metabolic syndrome and CAD risk, constitutes a new level of information available to public health authorities and health professionals. In this regard, genetic health determinants should be considered as one of the key components within a global systems approach needed to better understand the modulators of the risk of disease at the population or community level. Considering the endemization of obesity and related disorders worldwide, 36 it is also of interest to document genetic modulators of the 'hypertriglyceridemicwaist' phenotype with the intent of identifying new potential targets for treatment and prevention.
